📅 Next earnings: November 06, 2026
Moderna, Inc. (MRNA) — Pre-Earnings Stock Analysis
Healthcare, Biotechnology
🔥 Get MRNA Targets Before Earnings
Pre-earnings entry zone, analyst PE target, 3-day and 5-day implied move, and stop loss — all unlocked with a $5/month subscription.
Unlock Full Analysis →
About Moderna, Inc. (MRNA)
Moderna, Inc. trades on NASDAQ under the ticker MRNA. The company operates in the Healthcare sector — specifically Biotechnology.
Current analyst consensus rating: Hold with a $123 price target based on 18 analyst opinions.
EPS (trailing): $-7.98 | Market Cap: $82.5B
Healthcare Biotechnology
Pre-Earnings Trading Strategy for MRNA
Trading stocks before earnings requires understanding three key variables: the implied move (what the options market expects), the historical beat rate for the sector, and the current momentum leading into the report.
For MRNA, the next earnings report is scheduled for November 06, 2026.
The implied move is calculated using at-the-money straddles — if the straddle is priced at X%, the market is pricing in approximately a ±X% move in either direction around the earnings release.
- Buy before earnings when the implied move is lower than historical actual moves — the options are cheap relative to what the stock has historically done.
- Set a stop loss at 10% below entry for pre-earnings positions — earnings volatility can swing 20-30% on a miss.
- Sell within 5 days of a beat — momentum after a positive earnings surprise typically fades within a week as short-term traders take profits.
- Check short interest — high short interest (elevated) increases squeeze potential on a beat.
How AI Market Cap Finds Pre-Earnings Setups
Our pre-earnings momentum scanner scores MRNA across five factors to identify high-conviction setups:
- Analyst conviction — Strong Buy ratings from 18 analysts driving price targets above current market price.
- Implied volatility rank — Whether options premiums are attractively priced relative to historical volatility.
- Pre-earnings momentum — Whether the stock has been trending in the direction of the expected beat.
- Sector sentiment — How the broader Healthcare sector is positioned heading into this earnings cycle.
- Days to earnings — The sweet spot is 5-12 days before — enough time for momentum to develop, not enough time for premium decay to hurt.
The Pro subscription shows the full target range, stop loss, and implied move for MRNA and all 20+ stocks in the current earnings window.